Citius Oncology, Inc. filings document material-event disclosures for an oncology-focused biopharmaceutical company commercializing LYMPHIR™. Recent Form 8-K reports cover operating and financial results following the LYMPHIR launch, international shipment and distribution updates, clinical-study disclosures involving denileukin diftitox-cxdl, and press-release exhibits related to commercial and medical developments.
The filing record also includes emerging growth company disclosures, Nasdaq continued-listing notice reporting, and categories such as material agreements, shareholder voting matters, capital-structure disclosure, governance matters, and security-structure information. These documents frame CTOR’s public reporting around product commercialization, clinical development, corporate governance, listing compliance, and financing-related matters.
Citius Oncology reported preliminary, unaudited 120% growth in LYMPHIR unit shipments to U.S. wholesalers during the fiscal fourth quarter ended September 30, 2026, alongside institutional vial orders. The company said institutional demand continued and its expanded commercial team reached nationwide coverage in August. LYMPHIR, an FDA-approved therapy, was launched in the U.S. in December 2025 for relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy.
Citius Oncology said it was more than halfway toward its goal of placing LYMPHIR on formulary at 100 priority institutions by calendar year-end. Revenue is recognized when wholesaler orders are fulfilled and is based on units sold to wholesalers, net of estimated gross-to-net adjustments, rather than institutional vial orders. Management expects fourth-quarter momentum to carry into fiscal 2027, with continued institutional demand and sales growth.
The unit information is based on management’s estimates, remains subject to year-end closing procedures and audit, and actual results may differ. Complete fiscal fourth-quarter and fiscal 2026 results are expected in December 2026. Among the risks Citius Oncology lists are its need for substantial additional funds and its ability to raise money to fund operations for at least the next 12 months as a going concern.
Citius Oncology, Inc. (CTOR) received Nasdaq’s extension through April 19, 2027 to evidence compliance with the $1.00-per-share minimum bid-price requirement for continued listing on the Nasdaq Capital Market. Before that date, the common stock must close at $1.00 per share or more for a minimum of ten consecutive business days to regain compliance.
If Citius Oncology does not regain compliance by April 19, 2027, Nasdaq will notify the company that its common stock is subject to delisting; the company may appeal the determination to a Nasdaq hearings panel. The extension does not change the stock’s current listing, and it continues to trade on the Nasdaq Capital Market. Citius Oncology is evaluating options to regain compliance and says there can be no assurance it will do so.
Citius Oncology, Inc. (CTOR) stockholders elected Dr. Eugene Holuka, Robert Smith and Carol Webb as Class II directors for three-year terms expiring at the 2029 annual meeting, or until successors are duly elected and qualified. Holuka received 67,835,202 votes for and 8,267,153 withheld; Smith received 67,883,403 for and 8,218,952 withheld; Webb received 67,895,374 for and 8,206,981 withheld. Each nominee had 6,255,142 broker non-votes.
Stockholders also ratified Wolf & Company, P.C. as independent registered public accounting firm for the fiscal year ended September 30, 2026: 73,533,649 votes for, 8,809,478 against, 14,370 abstentions and no broker non-votes.
Citius Oncology, Inc. (CTOR) is calling its 2026 Annual Meeting of Stockholders for September 29, 2026 at its Cranford, New Jersey headquarters. Holders of 92,981,204 common shares as of August 17, 2026 may vote.
Stockholders will vote on electing three Class II directors (Dr. Eugene Holuka, Robert Smith and Carol Webb) to terms expiring at the 2029 annual meeting, and on ratifying Wolf & Company, P.C. as auditor for the fiscal year ending September 30, 2026. Directors are elected by plurality; the auditor ratification requires a majority of votes represented and entitled to vote.
The nine‑member board is classified into three classes and a majority, including all committee members, is independent; Leonard Mazur (Chairman and CEO) and Myron Holubiak (Secretary and Executive Vice Chairman) are not independent. Citius Pharmaceuticals, Inc. owns 66,049,615 shares, or 71.0%, and also provides shared services under an agreement with a quarterly fee of about $940,000. Executive compensation relies on salary and equity awards, with a clawback policy, insider trading policy, and emerging‑growth‑company scaled disclosure.
CITIUS ONCOLOGY, INC. director Jonathan Peri filed an initial Form 3 reporting his equity position in the company. The filing lists a holding entry for Common Stock with 0 shares reported as directly owned following the reported position.
Citius Oncology, Inc. filed a prospectus supplement updating its registration for 6,818,182 shares of common stock underlying warrants that were exercised at $0.90 per share under a warrant inducement agreement, generating approximately $6.1 million in net proceeds. An additional 272,727 shares remain issuable under placement agent warrants. The company’s Form 10-Q for the quarter ended June 30, 2026 reports $1.5 million in quarterly LYMPHIR product revenue and $7.1 million for the nine months, but also a net loss of $41.1 million and cash of $16.6 million. Citius Oncology discloses substantial doubt about its ability to continue as a going concern beyond November 2026 without additional financing and notes a Nasdaq minimum bid-price deficiency. It entered a term loan facility of up to $25.0 million, with $10.0 million drawn at a minimum interest rate of 12.75%, and incurred significant termination and cancellation fees related to a prior manufacturing contract. The company also expanded its board to nine directors with the appointment of independent director Jonathan Peri and continues the commercial rollout and international access programs for LYMPHIR.
Citius Oncology, Inc. reported its first meaningful commercial period following the December 2025 launch of LYMPHIR, an immunotherapy for cutaneous T‑cell lymphoma. For the nine months ended June 30, 2026, LYMPHIR generated $7.1 million in revenue with about 77% gross profit, and total assets were $112.1 million, including $69.4 million of in‑process R&D and $22.6 million of inventory.
The company remains highly loss‑making, with a nine‑month net loss of $41.1 million, accumulated deficit of $105.1 million, and negative working capital of roughly $16.1 million. A former contract manufacturer terminated its agreement, triggering about $20.1 million of termination fees and a related $19.7 million contract cancellation charge.
Citius Oncology ended the quarter with $16.6 million in cash, supported by $9.7 million of warrant‑exercise proceeds and an up to $25.0 million secured term loan, of which $10.0 million has funded. Management expects existing resources, together with support from majority owner Citius Pharmaceuticals, to fund operations only through November 2026 and discloses substantial doubt about continuing as a going concern.
Citius Oncology, Inc. reported fiscal third quarter 2026 results driven by the U.S. launch of LYMPHIR for cutaneous T‑cell lymphoma. For the quarter ended June 30, 2026, the company generated $1,493,788 in revenue, with $7,105,197 in revenue over the first nine months of fiscal 2026. Institutional demand for LYMPHIR is growing: vial orders rose from 708 in the quarter ended March 31, 2026 to 926 in the quarter ended June 30, 2026, and institutions ordered 383 vials in July, the largest monthly total to date. LYMPHIR has been ordered by 44 institutions since launch.
Despite this commercial traction, the company remains loss‑making. The third quarter net loss was $8,923,846, and the nine‑month net loss was $41,067,610, reflecting total operating expenses of $9,718,762 in the quarter and $48,077,956 year‑to‑date, including substantial general and administrative and stock‑based compensation expenses. As of June 30, 2026, Citius Oncology held $16,563,705 in cash and cash equivalents, total assets of $112,093,103, liabilities of $71,708,109, and stockholders’ equity of $40,384,994. Management highlights expanding commercial and medical affairs teams and ongoing studies to support broader LYMPHIR adoption.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 9,353,553 shares of Citius Oncology, Inc. common stock, representing 9.99% of the class. They hold shared voting and dispositive power over all 9,353,553 shares and no sole voting or dispositive power.
The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. Through this role, Armistice Capital and Mr. Boyd may be deemed to beneficially own the Master Fund’s holdings. The Master Fund has the economic right to receive dividends and sale proceeds on these securities.